Amgen to buy Abgenix for $2.2B

Amgen has struck a deal to buy Abgenix for $2.2 billion in cash. The California-based Abgenix was able to fetch the price by providing Amgen with two experimental therapies that could turn into blockbusters. Its lead candidate is the colon cancer treatment panitumumab, which has demonstrated an ability to control tumor growth. Abgenix develops therapies by genetically engineering mice to produce antibodies. An Amgen spokesperson says the deal gives Amgen its first therapy for tumors.

"This investment reflects Amgen's commitment to our pipeline and our growing confidence in the future success of both panitumumab and denosumab," said Kevin Sharer, president and CEO of Amgen.

- read this report in the San Jose Mercury News for more information

Suggested Articles

Wedding Five Prime Therapeutics’ cabiralizumab to Bristol-Myers Squibb’s checkpoint inhibitor Opdivo has proved to be a bust in pancreatic cancer.

Sean Harper and Beth Seidenberg tell FierceBiotech how and why they set up their own VC firm, Westlake Village BioPartners.

Imara is looking to cap a good 2019 with an initial public offering in 2020. The rare disease biotech wants $86 million on the Nasdaq.